Hostname: page-component-78c5997874-ndw9j Total loading time: 0 Render date: 2024-11-03T05:12:04.174Z Has data issue: false hasContentIssue false
  • English
  • Français

Use of LH-RH agonists in the treatment of breast disease

Published online by Cambridge University Press:  05 December 2011

R. I. Nicholson  and
K. J. Walker
R. I. Nicholson
Affiliation:
Tenovus Institute for Cancer Research, University of Wales College of Medicine, Heath Park, Cardiff, CF4 4XX, U.K.
K. J. Walker
Affiliation:
Tenovus Institute for Cancer Research, University of Wales College of Medicine, Heath Park, Cardiff, CF4 4XX, U.K.
Get access

Synopsis

The effects of LH-RH agonists in advanced breast cancer patients are reviewed and compared to the efficacy of surgical ablation of the ovaries and X-ray induced menopause in the treatment of this disease. In both pre- and postmenopausal women, LH-RH agonists produce pituitary gland desensitisation and a fall in concentrations of LH and FSH. In premenopausal patients plasma progesterone and oestradiol levels fall to the castrate or postmenopausal range within three to four weeks. Tumour remissions have been observed in approximately 30% of premenopausal women (50% ER-positive) and approximately 10% of postmenopausal patients. The mechanism of action of LH-RH agonists is discussed and their current application to combined endocrine therapy, early breast cancer and mastalgia briefly outlined.

Type
Research Article
Information
Proceedings of the Royal Society of Edinburgh, Section B: Biological Sciences , Volume 95: Oestrogen and the Human Breast , 1989 , pp. 271 - 281
Copyright
Copyright © Royal Society of Edinburgh 1989

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Beksac, M. S., Kisnisci, H. A., Cakar, A. N. & Beksac, M. 1983. The endocrinological evaluation of bilateral and unilateral oophorectomy in premenopausal women. International Journal of Fertility 28, 219–224.Google ScholarPubMed
Blankenstein, M. A., Henkelman, M. S. & Klijn, J. G. M. 1985. Direct Inhibitory effect of an LH-RH agonist on MCF-7 human breast cancer cells. European Journal of Cancer and Clinical Oncology 21, 1493–1499.CrossRefGoogle ScholarPubMed
Campbell, F. C., Blamey, R. W., Elston, C. W., Morris, A. H., Nicholson, R. I., Griffiths, K. & Haybittle, J. L. 1981. Quantitative oestradiol receptor values in primary breast cancer and response of metastases to endocrine therapy. Lancet ii, 1317–1319.CrossRefGoogle Scholar
Dembinskii, T. C., Leung, L. K. H. & Shiu, R. P. C. 1985. Evidence for a novel pituitary factor that potentiates the mitogenic effect of oestrogen in human breast cancer cells. Cancer Research 45, 3083–3089.Google Scholar
Dowsett, M., Cantwell, B., Anshumala, Lal, Jeffcoate, S. L. & Harris, A. L. 1988. Suppression of postmenopausal ovarian steroidogenesis with the luteinizing hormone-releasing hormone agonist goserelin. Journal of Clinical Endocrinology and Metabolism 66, 672–677.CrossRefGoogle ScholarPubMed
Dresser, R. 1936. Effect of ovarian irradiation on bone metastasis of cancer of the breast. American Journal of Roentgenology 35, 384–391.Google Scholar
Dulfour, J., Cahill, L. P. & Maulean, P. 1979. Short and long-term effects of hypophysectomy and unilateral ovariectomy on ovarian follicular populations in sheep. Journal of Reproduction and Fertility 57, 301–309.CrossRefGoogle Scholar
Eidne, K. A., Flanagan, C. A. & Millar, R. P. 1985. Gonadotropin-releasing hormone binding sites in human breast carcinoma. Science 229, 989–991.CrossRefGoogle ScholarPubMed
Fracchia, A. A., Farrow, J. H., DePalo, A. J., Connolly, D. P. & Huvos, A. G. 1969. Castration for primary inoperable or recurrent breast carcinoma. Surgery, Gynecology and Obstetrics 128, 1226–1234.Google ScholarPubMed
Furr, B. J. A. & Nicholson, R. I. 1982. Use of analogues of luteinizing hormone-releasing hormone for the treatment of cancer. Journal of Reproduction and Fertility 64, 529–539.CrossRefGoogle ScholarPubMed
Harvey, H. A. 1988. Luteinizing hormone-releasing hormone agonists in the therapy of breast cancer. In Endocrine Therapies in Breast and Prostate Cancer, ed. Osborne, C. K., pp. 39–50. Boston: Kluwer Acad. Publishers.CrossRefGoogle Scholar
Harvey, H. A., Lipton, A. & Max, D. T. 1987. LH-RH agonist treatment of breast cancer; a phase II study in the USA. In Hormonal Manipulation of Cancer, eds Klijn, J. G. M., Paridens, R. & Foekens, J. A., pp. 321–330. New York: Raven Press.Google Scholar
Hirshfield, A. N. 1985. Comparison of granulosa cell proliferation in small follicles of hypophysectomized, prepubertal and mature rats. Biology of Reproduction 32, 979–987.CrossRefGoogle ScholarPubMed
Hoffken, K., Miller, B., Fisher, P. & 6 others. 1986. Buserelin in Treatment of premenopausal advanced breast cancer. European Journal of Cancer and Clinical Oncology 22, 746 P.CrossRefGoogle Scholar
Judd, H. L., Lucas, W. E. & Yen, S. S. C. 1974. Effect of oophorectomy on circulating testosterone and androstenedione levels in patients with endometrial cancer. American Journal of Obstetrics and Gynecology 118, 793.CrossRefGoogle ScholarPubMed
Kardinal, C. G. & Donegan, W. L. 1979. Endocrine and hormonal therapy. In Cancer of the Breast, 2nd edn, eds Donegan, W. L. & Spratt, V. S., Vol. 5 in the series Major Problems in Clinical Surgery, pp. 361–404. London: W. B. Saunders Company.Google ScholarPubMed
Klijn, J. G. M., Van Geel, A. N., Sandow, J. & De Jong, F. H. 1988. Treatment with high dose LH-RH agonist (Buserelin) plus tamoxifen and with buserelin implants in premenopausal patients; an endocrine and pharmacokinetic study. In 3rd International Congress on Hormones and Cancer, New York: Raven Press.Google Scholar
Klijn, J. G. M. & De Jong, F. H. 1987. Long-term LH-RH agonist (Buserelin) treatment in metastatic premenopausal breast cancer. In Hormonal Manipulation of Cancer, eds Klijn, J. G. M., Paridens, R. & Foekens, J. A., pp. 343–352. New York: Raven Press.Google Scholar
Lee, Y. T. & Hori, J. M. 1971. Significance of ovarian metastasis in therapeutic oophorectomy of advanced breast cancer. Cancer 27 (6), 1374–1378.3.0.CO;2-M>CrossRefGoogle ScholarPubMed
Mansel, R. E. 1988. Investigation and treatment of cyclical benign breast disease. In Functional Disorders of the Menstrual Cycle, eds Brush, M. G. & Goudsmit, E. M., pp. 191–198. Chichester: John Wiley and Sons, Ltd.Google Scholar
Mathé, G., Keiling, R., Prevot, G. & 10 others. 1987. LH-RH agonist: Breast and Prostate Cancer. In Hormonal Manipulation of Cancer, eds Klijn, J. G. M., Paridens, R. & Foekens, J. A., pp. 315–319. New York: Raven Press.Google Scholar
Maynard, P. V. & Nicholson, R. I. 1979. Biological effects of high dose levels of a series of new LH-RH analogues to intact female rats. British Journal of Cancer 39, 274–279.CrossRefGoogle Scholar
Miller, W. R., Scott, W. N., Morris, R., Fraser, H. M. & Sharpe, R. M. 1985. Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature 313, 231–233.CrossRefGoogle ScholarPubMed
Miller, W. R., Scott, W. N., Fraser, H. M. & Sharpe, R. M. 1987. Direct inhibition of human breast cancer cell growth by an LH-RH agonist. In Hormonal Manipulation of Cancer, ed. Klijn, J. G. M., Paridens, R. & Foekens, J. A., pp. 357–368. New York: Raven Press.Google Scholar
Nicholson, R. I., Walker, K. J. & Maynard, P. V. 1980. Anti-tumour potential of a new luteinizing hormone-releasing hormone analogue ICI 118630. In Breast Cancer, Experimental and Clinical Aspects, eds Mouridsen, H. T. & Palshof, T., pp. 295–299. Oxford: Pergamon Press.Google Scholar
Nicholson, R. I., Walker, K. J., Harper, M., Phillips, A. D. and Furr, B. J. A. 1983. Future use of luteinizing hormone-releasing hormone agonists in the therapy of breast cancer in pre- and post-menopausal women. In Reviews on Endocrine-Related Cancer: Breast Cancer, (Suppl. 13), eds Nicholson, R. I. & Griffiths, K., pp. 55–62. Macclesfield: ICI Publications.Google Scholar
Nicholson, R. I., Walker, K. J., Davies, P. & and 7 others. 1984a. Use and mechanism of action of the LH-RH agonist ICI 118630 in the therapy of hormone sensitive breast and prostate cancer, In Hormones and Cancer 2, Proceedings of the International Congress on Hormones and Cancer, eds Bresciani, F., King, R. J. B. & Lippman, M. F., pp. 519–532. New York: Raven Press.Google Scholar
Nicholson, R. I., Walker, K. J., Turkes, A. et al. , 1984b. Therapeutic significance and mechanism of action of the LH-RH agonist ICI 118630 in breast and prostate cancer. Journal of Steroid Biochemistry 20, 129–135.CrossRefGoogle ScholarPubMed
Nicholson, R. I., Walker, K. J. & Davies, P. 1987a. Hormone agonists and antagonists in the treatment of hormone sensitive breast and prostate cancer. Cancer Surveys 5(3), 463–486.Google Scholar
Nicholson, R. I., Walker, K. J., Turkes, A. & 6 others. 1987b. The British Experience with the LH-RH agonist Zoladex (ICI 118630) in the treatment of Breast Cancer. In Hormonal Manipulation of Cancer, eds Klijn, J. G. M., Paridens, R. & Foekens, J. A., pp. 331–341. New York: Raven Press.Google Scholar
Nicholson, R. I., Gotting, K. E., Gee, J. & Walker, K. J. 1988. Actions of oestrogens and antioestrogens on rat mammary gland development: relevance to breast cancer prevention. Journal of Steroid Biochemistry 30, 95–103.CrossRefGoogle ScholarPubMed
Nicholson, R. I. & Maynard, P. V. 1979. Antitumour activity of ICI 118630, a new potent luteinizing hormone-releasing hormone agonist. British Journal of Cancer 39, 268–273.CrossRefGoogle ScholarPubMed
Nicholson, R. I. & Walker, K. J. 1988. Preclinical studies and antitumour mechanism of action of LH-RH analogues. In Endocrine Therapies in Breast and Prostate Cancer, ed. Osborne, C. K., pp. 1–23. Boston: Kluwer Acad. Publishers.Google Scholar
Nillius, S. J. 1984. Luteinizing hormone-releasing hormone analogues for contraception. Clinical Obstetrics and Gynecology 11, 551–572.CrossRefGoogle ScholarPubMed
Nissen-Meyer, R. 1965. Castration as part of the primary treatment for operable female breast cancer. Acta Radiologica. Supplementum 249.Google Scholar
Nolvadex Adjuvant Trial Organisation 1985. Controlled trial of tamoxifen as single adjuvant agent in the management of early breast cancer. Analysis at six years. Lancet i, 836–840.Google Scholar
Plowman, P. N., Walker, K. J. & Nicholson, R. I. 1986. Remissions of postmenopausal breast cancer during treatment with luteinizing hormone-releasing hormone agonist ICI 118630. British Journal of Cancer 54, 903–909.CrossRefGoogle ScholarPubMed
Porter, R. N., Smith, W. & Craft, I. L. 1984. Induction of ovulation for in vitro fertilization using Buserelin and gonadotrophins. Lancet 2, 1284–1285.CrossRefGoogle Scholar
Rose, C., Mouridsen, H. T., Thorpe, S. M., Anderson, J., Blichert-Toft, M. & Anderson, K. W. 1985. Antioestrogen treatment of postmenopausal women with primary high-risk breast cancer; six years of life-table analysis. Reviews on Endocrine Related Cancer Suppl. 17, 17–24.Google Scholar
Schally, A. V., Redding, T. W. & Comaru-Schally, A. V. 1984. Potential use of analogues of luteinizing hormone-releasing hormone in the treatment of hormone sensitive neoplasms. Cancer Treatment Reports 68, 281–289.Google ScholarPubMed
Taylor, S. G. 1962. Endocrine ablation in disseminated mammary carcinoma. Surgery, Gynecology and Obstetrics 115, 443–448.Google ScholarPubMed
The Scottish Trial Group 1987. Adjuvant tamoxifen in the management of operable breast cancer. Lancet ii, 171–175.Google Scholar
Treves, N. & Finkbeiner, J. A. 1958. An evaluation of therapeutic surgical castration in the treatment of metastatic, recurrent, and primary inoperable mammary carcinoma in women. An analysis of 191 patients. Cancer 11, 421–438.3.0.CO;2-L>CrossRefGoogle ScholarPubMed
Vermeulen, A. 1976. The hormonal activity of the postmenopausal ovary. Journal of Clinical Endocrinology and Metabolism 42, 247–253.CrossRefGoogle ScholarPubMed
Walker, K. J., Turkes, A., Williams, M., Blamey, R. W. & Nicholson, R. I. 1986. Preliminary endocrinological evaluation of a sustained-release formulation of the LH-releasing hormone agonist D-Ser (But)6 Azgly10 LH-RH in premenopausal women with advanced breast cancer. Journal of Endocrinology 111, 349–353.CrossRefGoogle Scholar
Walker, K. J., Turkes, A., Robertson, J. F. R., Blarney, R. W., Griffiths, K. & Nicholson, R. I. 1989. Endocrine effects of combination antioestrogen and LH-RH agonist therapy in premenopausal advanced breast cancer patients. European Journal of Cancer and Clinical Oncology (in press).CrossRefGoogle Scholar
Waxman, J. H., Harland, S. J., Coombes, R. C. & 4 others. 1985. The treatment of postmenopausal women with advanced breast cancer with Buserelin. Cancer Chemotherapy and Pharmacology 15, 171–173.CrossRefGoogle ScholarPubMed
Wilding, G., Chen, M. & Gelmann, E. P. 1987. LH-RH agonists and human breast cancer cells. Nature 329, 770.CrossRefGoogle ScholarPubMed
Williams, M. R., Walker, K. J., Turkes, A., Elston, C. W., Blamey, R. W. & Nicholson, R. I. 1986. The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer. British Journal of Cancer 53, 629–636.CrossRefGoogle ScholarPubMed
Williams, M. & Nicholson, R. I. 1986. The Premenopausal women: treatment of secondary breast cancer In Complications in the management of breast disease, ed. Blamey, R. W., pp. 128–136. Eastbourne: Baillière Tindall.Google Scholar
Williamson, K., Robertson, J. F. R., Ellis, I. O., Elston, C. W., Nicholson, R. I. & Blarney, R. W. 1988. Effect of LH-RH agonist, Zoladex on ovarian histology. British Journal of Surgery 75, 595–596.CrossRefGoogle ScholarPubMed
Wonder, H. E. 1987. A long acting depot preparation of a synthetic GnRH agonist (Zoladex) in the treatment of pre- and post-menopausal breast cancer. Journal of Steroid Biochemistry 27, Abstract C017.Google Scholar